PRAX
HealthcarePraxis Precision Medicines, Inc.
$276.92
$-9.48 (-3.31%)
Jan 5, 2026
Price History (1Y)
Analysis
Praxis Precision Medicines, Inc. is a biotechnology company listed in the healthcare sector with a market capitalization of $6.92 billion. It has a relatively small workforce of 116 employees and its revenue for the trailing twelve months (TTM) stands at $7.46 million. The company's financial health is concerning, with net income of -$273 million, EBITDA of -$292.95 million, and free cash flow of -$133.37 million for the TTM period. Its gross margin, operating margin, and profit margin are all 0%, indicating significant losses. The return on equity (ROE) and return on assets (ROA) are also negative at -75.2% and -45.1%, respectively. Praxis Precision Medicines has a debt-to-equity ratio of 0.13 and cash reserves of $267.16 million, which is higher than its debt of $436,000. The company's valuation metrics indicate that it is currently trading at a price to book ratio of 17.06 and a price to sales ratio of 927.91. Its forward P/E ratio is -21.86, suggesting significant losses in the future. The beta of 2.88 indicates higher volatility compared to the market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $6.92B
- P/E Ratio
- N/A
- 52-Week High
- $317.72
- 52-Week Low
- $26.70
- Avg Volume
- 1.09M
- Beta
- 2.88
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 116